Caxton Corp Scynexis Inc Transaction History

Caxton Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.56 - $6.66 $88,426 - $165,427	-24,839 Reduced 1.42%	1,723,947 $6.74 Million
Q4 2021 Feb 14, 2022	BUY	$4.94 - $7.69 $910,866 - $1.42 Million	184,386 Added 11.79%	1,748,786 $10.7 Million
Q3 2021 Nov 15, 2021	BUY	$5.3 - $7.89 $401,618 - $597,880	75,777 Added 5.09%	1,564,400 $8.29 Million
Q2 2021 Aug 16, 2021	BUY	$6.5 - $9.97 $524,790 - $804,947	80,737 Added 5.73%	1,488,623 $11 Million
Q1 2021 May 17, 2021	SELL	$6.93 - $9.63 $460,734 - $640,240	-66,484 Reduced 4.51%	1,407,886 $11.2 Million

Q4 2020 Feb 16, 2021	BUY	$4.28 - $7.87 $2.74 Million - $5.04 Million	640,000 Added 76.7%	1,474,370 $11.3 Million
Q3 2020 Nov 16, 2020	BUY	$4.37 - $7.48 $3.65 Million - $6.24 Million	834,370 New	834,370 $3.68 Million

15.4M

12.9K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $63.7M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.